KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
The companies will work with investigators to share the results with the scientific community
Subscribe To Our Newsletter & Stay Updated